Sugi Predict

Sugi Predict / Compounds / SCHEMBL941444

SCHEMBL941444

SCHEMBL941444

O=C(O)c1cccc(-c2ccsc2)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 2/20 0.61
▸ KAT6A Q92794 2/20 0.57
▸ RXRA P19793 2/20 0.54
▸ RXRB P28702 2/20 0.54
▸ ACMSD Q8TDX5 1/20 0.54
▸ CYP2E1 P05181 1/20 0.53
▸ CYP2A6 P11509 1/20 0.53
▸ CYP2B6 P20813 1/20 0.53
▸ LCK P06239 1/20 0.52
▸ FYN P06241 1/20 0.52
▸ DAO P14920 1/20 0.52
▸ DRD2 P14416 2/20 0.49
▸ DRD4 P21917 2/20 0.49
▸ P2RY14 Q15391 1/20 0.48
▸ CNR1 P21554 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ ERN1 O75460 1/20 0.47
▸ KEAP1 Q14145 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27624169 0.87 KAT6A (0.55) KMOKAT6AACMSDCYP2E1CYP2A6
SCHEMBL28021307 0.86 KAT6A (0.58) KMOKAT6AACMSDCYP2E1CYP2A6
SCHEMBL28850615 0.85 LCK (0.59) KMOKAT6AACMSDCYP2E1CYP2A6
SCHEMBL6664611 0.84 CHEK2 (0.55) KAT6AACMSDCYP2E1CYP2A6CYP2B6
SCHEMBL12641873 0.84 KAT6A (0.52) KAT6AACMSDCYP2E1CYP2A6CYP2B6
SCHEMBL5924960 0.83 P2RY14 (0.58) KMOKAT6AACMSDCYP2E1CYP2A6
SCHEMBL29904709 0.82 KMO (0.86) KMORXRARXRBDAOLMNA
SCHEMBL30725957 0.82 KMO (0.86) KMORXRARXRBDAOLMNA
SCHEMBL71238 0.82 KMO (0.86) KMORXRARXRBDAOLMNA
Hydrochloric Acid SCHEMBL4350309 0.80 KMO (0.83) KMORXRARXRBLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160361295-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-12-15 — — US disclosed
EP-1815206-B1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS INC (US) 2016-04-06 — — EP disclosed
US-20160015685-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-01-21 — — US disclosed
US-20150164912-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2015-06-18 — — US disclosed
US-8933109-B2 Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors AMURA LIMITED (GB) 2015-01-13 — — US disclosed
US-20140038944-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2014-02-06 — — US disclosed
US-8552202-B2 Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors AMURA THERAPEUTICS LIMITED (GB) 2013-10-08 — — US disclosed
US-20130150345-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2013-06-13 — — US disclosed
US-8389737-B2 Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors AMURA THERAPEUTICS LIMITED (GB) 2013-03-05 — — US disclosed
EP-2297162-B1 COMPOUNDS AMURA THERAPEUTICS LTD (GB) 2012-08-15 — — EP disclosed
EP-0914165-A4 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY PHERIN PHARM INC (US) 2004-01-21 — — EP disclosed
CN-1444573-A Carboxamide compounds and their use as antagonists of the human 11CBY receptor SMITHKLINE BEECHAM PLC (GB) 2003-09-24 — — CN disclosed
EP-1305304-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR SMITHKLINE BEECHAM PLC (GB) 2003-05-02 — — EP disclosed
WO-2002010146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR SMITHKLINE BEECHAM P.L.C. (GB) 2002-02-07 — — WO disclosed
US-5968985-A INHIBITORS OF SODIUM ION/HYDROGEN ION EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-19 — — US disclosed
EP-0914165-A1 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY Pherin Pharmaceuticals, Inc. (US) 1999-05-12 — — EP disclosed
WO-1998014194-A9 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY — 1998-08-27 — — WO disclosed
WO-1998003207-A9 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY — 1998-05-22 — — WO disclosed
WO-1998014194-A1 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY PHERIN PHARMACEUTICALS (US) 1998-04-09 — — WO disclosed
WO-1998003207-A1 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY PHERIN PHARMACEUTICALS, INC. (US) 1998-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150345-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK KMO 546/4885KAT6A 1575/4885RXRA 4467/4885
US-20160015685-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK KMO 495/4885KAT6A 1831/4885RXRA 4499/4885
US-20160361295-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK KMO 546/4885KAT6A 1575/4885RXRA 4467/4885
US-20150164912-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK KMO 546/4885KAT6A 1575/4885RXRA 4467/4885
US-20140038944-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK KMO 546/4885KAT6A 1575/4885RXRA 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.